Post-published clinical data does not always save you (T 0251/25, Empagliflozin) By Dr Rose Hughes on Monday, October 19, 2026 article 83 epc Board of Appeal epo patents PatKat plausibility Rose Hughes second medical use +
When do you file for a drug combination invention? (T592/24) By Dr Rose Hughes on Monday, June 22, 2026 G2/21 patents PatKat plausibility Rose Hughes +
Fordham 33 (Report 4): Life sciences and healthcare innovation By Annsley Merelle Ward on Tuesday, April 14, 2026 #IPKat #UPC AmeriKat CJEU clinical trial disclosure fordham 33 Japan plausibility pricing SPC transparency +
Sufficiency at the priority date: A study protocol is not "the same" as a therapeutic effect invention (T0883/23) By Dr Rose Hughes on Wednesday, October 29, 2025 epo G 2/21 G2/21 obvious to try patents PatKat plausibility Rose Hughes Second medical use +
Patentee's own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23) By Dr Rose Hughes on Wednesday, October 22, 2025 antibody inventions epo functional claim language patents PatKat plausibility Rose Hughes sufficiency +
Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy By Dr Rose Hughes on Tuesday, May 27, 2025 antibody inventions epo event report G 1/24 G 2/21 patents PatKat pharma patents plausibility Rose Hughes upc +
UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 By Annsley Merelle Ward on Friday, May 09, 2025 #IPKat AstraZeneca epc G 2/21 Michael Tappin QC patent litigation plausibility SPC sufficiency Teva UK +
The plausibility of diagnostic inventions: No data, no patent (T 0589/22) By Dr Rose Hughes on Tuesday, April 29, 2025 diagnostic methods epo G2/21 patents PatKat plausibility post-published data Rose Hughes sufficiency +